Literature DB >> 2803984

Binding of von Willebrand factor to glycoproteins Ib and IIb/IIIa complex: affinity is related to multimeric size.

A B Federici1, R Bader, S Pagani, M L Colibretti, L De Marco, P M Mannucci.   

Abstract

We have separated von Willebrand factor (vWF) multimers of different size into several fractions which were characterized by SDS-agarose gel electrophoresis and by measuring the ratio between ristocetin cofactor activity (Ricof) and von Willebrand antigen (vWF:Ag) content. The pooled fractions contained vWF with multimeric structures and Ricof similar to those in plasma. The pool was labelled with 125I and used for inhibition binding studies with individual fractions to calculate the dissociation constants (Kd values expressed in mol/l) of the individual fractions for ristocetin-dependent binding to GP Ib and thrombin-induced binding to GP IIb/IIIa. Direct binding studies of the 125I-vWF pool gave mean Kd values of 2.02 +/- 0.05 x 10(-8) for GP Ib and 1.15 +/- 0.02 x 10(-8) for the GP IIb/IIIa complex. Inhibition binding studies gave Kd mean values one third to one tenth as high for larger multimers and 3-10 times higher for smaller multimers, for both GP Ib and IIb/IIIa complex. Similar results were observed when binding studies were carried out in the presence of platelets from a patient with afibrinogenaemia. These data on binding correlated very well with ristocetin- and thrombin-induced aggregation of afibrinogenaemic platelets, since equal concentrations of the higher molecular weight forms gave significantly higher aggregation rates. Based on these results, we conclude that the affinity of the vWF molecule for its two platelet receptors is greater for the largest multimers.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2803984     DOI: 10.1111/j.1365-2141.1989.tb00226.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  28 in total

1.  Pharmacokinetics and hemostatic effect of different factor VIII/von Willebrand factor concentrates in von Willebrand's disease type III.

Authors:  S Lethagen; E Berntorp; I M Nilsson
Journal:  Ann Hematol       Date:  1992-12       Impact factor: 3.673

2.  Evaluation of the effect of 6 von Willebrand factor concentrates on platelet adhesion to human vein segments under flow conditions.

Authors:  Wolfgang Mouton; Jerzy Madon; Joerg Fehr; Thomas Bombeli
Journal:  Int J Hematol       Date:  2004-11       Impact factor: 2.490

3.  Cav3.1 (alpha1G) controls von Willebrand factor secretion in rat pulmonary microvascular endothelial cells.

Authors:  Chun Zhou; Hairu Chen; Fengmin Lu; Hassan Sellak; Jonathan A Daigle; Mikhail F Alexeyev; Yaguang Xi; Jingfang Ju; Jan A van Mourik; Songwei Wu
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2006-12-15       Impact factor: 5.464

Review 4.  Role of von Willebrand factor in the haemostasis.

Authors:  Flora Peyvandi; Isabella Garagiola; Luciano Baronciani
Journal:  Blood Transfus       Date:  2011-05       Impact factor: 3.443

5.  Pathological von Willebrand factor fibers resist tissue plasminogen activator and ADAMTS13 while promoting the contact pathway and shear-induced platelet activation.

Authors:  B A Herbig; S L Diamond
Journal:  J Thromb Haemost       Date:  2015-07-28       Impact factor: 5.824

Review 6.  Diagnostic approach to von Willebrand disease.

Authors:  Christopher Ng; David G Motto; Jorge Di Paola
Journal:  Blood       Date:  2015-02-23       Impact factor: 22.113

7.  The importance of vicinal cysteines, C1669 and C1670, for von Willebrand factor A2 domain function.

Authors:  Brenda M Luken; Luke Y N Winn; Jonas Emsley; David A Lane; James T B Crawley
Journal:  Blood       Date:  2010-03-30       Impact factor: 22.113

8.  Distinct abnormalities in the interaction of purified types IIA and IIB von Willebrand factor with the two platelet binding sites, glycoprotein complexes Ib-IX and IIb-IIIa.

Authors:  L De Marco; M Mazzucato; D De Roia; A Casonato; A B Federici; A Girolami; Z M Ruggeri
Journal:  J Clin Invest       Date:  1990-09       Impact factor: 14.808

9.  Molecular modeling of the von Willebrand factor A2 Domain and the effects of associated type 2A von Willebrand disease mutations.

Authors:  Jeffrey J Sutherland; Lee A O'Brien; David Lillicrap; Donald F Weaver
Journal:  J Mol Model       Date:  2004-08-03       Impact factor: 1.810

10.  Heterogeneity of plasma von Willebrand factor multimers resulting from proteolysis of the constituent subunit.

Authors:  J A Dent; M Galbusera; Z M Ruggeri
Journal:  J Clin Invest       Date:  1991-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.